Survival outcomes according to TIMP1 and EGFR expression in heavily treated patients with advanced non-small cell lung cancer who received biweekly irinotecan plus bevacizumab
Cargando...
Fecha
2017
Título de la revista
Publicado en
Anticancer Research, 0250-7005, Vol. 37, Nro.11, 2017, p.6429-6436
Publicado por
International Institute of Anticancer Research
URL de la fuente
ISSN de la revista
Título del volumen
Resumen
Descripción
Abstract
Background: Heavily treated patients with nonsmall cell lung cancer (NSCLC) have few treatment options, while irinotecan and bevacizumab have proven synergistic action in preclinical studies. Patients and Methods: A total of 49 patients with heavily treated NSCLC were enrolled from 2011-2014 and treated with irinotecan and bevacizumab. Treatment response along with mutational status of epidermal growth factor receptor (EGFR), and tissue inhibitor of metalloproteinases-1 (TIMP1) and EGFR expression were evaluated. Progression-free (PFS) and overall (OS) survival were monitored. Results: Median follow-up was 13.2 months. Twenty-three patients had received three or more prior therapy lines. Overall response rate was 32% [95% confidence interval (CI)=22%-39%] and 26% of patients achieved stable disease. Median PFS was 4.4 (95% CI=2.8- 8.3) months and median OS 18.0 (95% CI=16.2-30.7) months. Nine patients harboring EGFR mutations had a longlasting partial response. A shorter OS was found in patients with a higher TIMP1 expression (p=0.006). Conclusion: Irinotecan combined with bevacizumab had favorable antitumor activity in heavily pretreated patients with NSCLC. These results suggest this is a reasonable strategy, particularly for patients with low TIMP1 expression.
Palabras clave
Keywords
Irinotecan, Bevacizumab, TIMP1, EGFR mutation, Gene expression
Temáticas
Tratamiento farmacológico
Calidad de vida
Neoplasias pulmonares
Calidad de vida
Neoplasias pulmonares